and graft biopsies were performed in 73 and 35 units, respectively. RB activity was highly variable among units, ranging from several hundred to <10 per year. Transjugular renal biopsy was judged to be smoothly accessible in 28 out of 73 units (38.4%). Significant variations in practices were observed regarding patient information before RB, assessment of haemorrhagic risk factors, management of patients with antiplatelet agents and haemorrhagic risk factors, and radiological guidance. Early discharge (<12 h) was the rule in 3 (4.1%) units for native kidney biopsies and in 10 (28.6%) units for graft biopsies. Conclusions. Our study is the first to provide a representative picture of 'everyday' RB practices in a country. Important variations in procedures were observed. Our study may
Introduction
Renal biopsy (RB) is often necessary for the diagnosis, prognostic assessment and therapy guidance of various diseases affecting native kidneys or transplants. As an invasive procedure, RB incurs a potential risk of bleeding complications of variable severity, from transitory gross haematuria or paucisymptomatic haematoma to massive bleeding requiring nephrectomy and, very rarely, death [1] [2] [3] .
Although several studies have revealed risk factors associated with bleeding [4] [5] [6] , the best ways to accurately identify patients who will develop complications and prevent complications from occurring remain elusive.
Transjugular renal biopsy (TJRB) has been reported to be a relatively safe and reliable alternative to conventional percutaneous RB in patients at high risk for bleeding [7] [8] [9] or obesity [10] . However, the necessity of well-trained interventional radiologists for this procedure likely limits TJRB availability at some institutions.
With the use of ultrasound (US)-guided renal biopsy and automated biopsy devices, RB has become safe, with recent studies reporting life-threatening complications in <0.1% of RB procedures [1, 4] . Because of the rarity of severe complications and an ongoing effort to limit costs, some have proposed that RB should be performed as an outpatient procedure [11, 12] . However, some authors have raised concerns against this practice [13, 14] .
The gold standard for RB procedures remains to be defined. It is likely that practices vary widely among nephrologists and mainly depend on personal experience and the availability of particular techniques. An audit on RB procedures in UK paediatric centres (11 centres included) was recently reported, highlighting a significant variation in clinical practice [15] . To our knowledge, studies investigating the practice of the RB procedure in adults have never been published. The purpose of our study was to depict the main aspects of the practice of RB in adults in France.
Material and methods
This study was realized in the setting of reflection on RB procedures by a working group appointed by the scientific commission of the Société de Néphrologie in France (the Francophone Society of Nephrology). The survey was conducted between 1 March 2009 and 30 September 2009, and was limited to RB for diagnosis of diffuse parenchymal grafts or native kidney diseases in adults, excluding RB for tumours. Information regarding the study was sent by e-mail to all members of the Société de Néphrologie. In all, this represented 1013 nephrologists in activity. Participants were informed of the purpose of the study and were asked to download and fill out a questionnaire, which included 33 questions, including the number of RB per year, proportion of grafts and native kidney biopsies, use of protocol graft biopsies, TJRB availability, number of TJRB and laparoscopic biopsies, patient information procedures, methods used to evaluate the risk for bleeding (including systematic questioning and haemostatic tests), radiological guidance, biopsy device used, duration of hospitalization and standard post-RB observation period. The questionnaire is available online as supplementary material. The completed questionnaires were then returned for analysis.
Because several nephrologists performing RB procedures in the same unit could participate in the study, there was a risk of overweighting the importance of some centres, independently of centre size and activity. To avoid this potential bias, only one answer was taken into account for each centre, and results were expressed in terms of centre when a question regarded activity of the nephrology unit rather than individual practices of nephrologists. In such cases, we ensured that all nephrologists in the same unit gave identical answers. For questions regarding individual practices that were likely to vary among nephrologists, including those in the same unit, all answers were included.
Statistical analysis
Quantitative parameters were presented as mean +/-standard error, and qualitative parameters were presented as numbers and percentages. Categorical variables were compared using the χ 2 test or Fisher exact test where appropriate. Continuous variables were compared using the Mann-Whitney U-test (two groups); P < 0.05 was considered as statistically significant.
Results

Nephrology units and nephrologists participating in the study
Eighty-eight nephrologists from 74 distinct units participated in our study ( Table 1 ). All responders were consultant nephrologists. As expected, nephrologists in the same unit gave identical answers to questions regarding activity of the nephrology unit rather than individual practices of nephrologists. This allowed us to take into account only one answer to these questions for each centre and to express results in term of centres. All units were located throughout metropolitan France, with the exception of three units in overseas France and one unit in Belgium (Figure 1 TJRB was judged to be smoothly accessible in 28 out of 73 units (38.4%). TJRBs were never performed in 40 (54.1%) units. In other units, TJRB represented 1-5% of total RB procedures in 25 (33.8%) units, 5-10% in 5 (6.8%) units, 10-20% in 3 (4.1%) units and >20% in 1 (1.4%) unit.
Surgical RB were rarely performed, representing <1% of total RB procedures in 70 (94.6%) units and 1-5% in 4 (5.4%) units.
In 23 out of 27 (85.2%) units located in teaching hospitals, some RB procedures were performed by residents. Residents performed no RB procedures in 4 (14.8%) units, 1-25% in 17 units (63%), 25-50% in 2 (7.4%) units and >50% in 1 (3.7%) unit.
RB procedures were performed by nephrologists alone in 37 (50%) units, by radiologists in 8 (10.8%) and by nephrologists assisted by radiologists in 29 (39.2%) units.
Patient information and consent before RB
Nephrologists were asked how they informed patients prior to RB regarding indication, potential complications, technique, monitoring and recommended post-procedure precautions (Table 2) . Information was provided orally only by 18 (20.5%) nephrologists, in writing only by 19 (21.6%), and both orally and in writing by 49 (55.7%) nephrologists. Two (2.2%) nephrologists indicated that they gave no detailed information before performing RB procedures. Patient consent in writing was obtained prior to RB by 39 (44.3%) nephrologists.
Assessment of haemorrhagic risk factors before RB
Before RB, patients were systematically questioned about their personal history of bleeding by 67 (76.1%), familial history of bleeding by 33 (37.5%), and anticoagulant or antiplatelet agent intake by 86 (97.8%) nephrologists (Table 2) .
Haemostatic tests that were systematically performed prior to RB were prothrombin time (PT) and activated partial prothrombin time (aPTT) by 88 (100%), platelet counts by 87 (98.9%), bleeding time by 50 (56.8%), and platelet function analyser (PFA100) by 10 (11.4%) nephrologists.
Nephrologists were asked whether they considered that some risk factors and results of haemostatic tests (and which limit values they considered) contraindicated percutaneous RB unless they could be corrected with an appropriate treatment; the results are provided in Table 3 .
RB in patients with antiplatelet agents and haemorrhagic risk factors
Nephrologists were asked about which options they routinely pursued in patients taking antiplatelet agents (Table 4) among the following propositions: surgical or TJRB, percutaneous RB without drug cessation, and percutaneous RB after drug cessation. Nephrologists were given the opportunity to provide several answers. Overall, 12 (15%) out of 80 nephrologists who answered the question chose the 'surgical or TJRB' option, 9 (11.3%) performed 'percutaneous RB without drug cessation' and 75 (93.8%) performed 'percutaneous RB after drug cessation'. The mean duration of antiplatelet agent cessation was 7.9 ± 2.2 days before and 6.0 ± 3.4 days after RB.
We studied nephrologist practices regarding RB procedures in patients taking antiplatelet agents according to the TJRB availability that they reported in their unit. There was a non-significant trend towards a lower rate of the 'surgical or TJRB' option [5/52 (9.6%) vs. 7/28 (25%)] and lower rates of the 'RB after drug cessation' option [48/52 (92.3%) vs. 27/28 (96.4%)] in the 52 nephrologists who reported inadequate TJRB availability compared to the 28 nephrologists with smooth access to TJRB. The 'percutaneous RB without drug cessation' option was significantly less frequently reported by nephrologists with inadequate TJRB availability [1/52 (1.9%) vs. 6/28 (21.4%), P < 0.01].
Nephrologists were also questioned about treatments they routinely administered to patients when a disorder of primary haemostasis was suspected, based on the results of tests or questioning. Platelet or red blood cell transfusions and DDAVP (66 nephrologists, 75.1%) were commonly given to such 'high-risk patients'. In contrast, the use of other treatments, such as oestrogens or cryoprecipitate, was not reported (Table 4) .
RB procedure
An automated biopsy gun and Tru-Cut needle (manual device) were used by 80 (90.9%) and 8 (9.1%) nephrologists, respectively. The needle gauge, reported by 60 nephrologists, varied from 12G to 18G, with 16G being the most commonly used gauge (35, 58.3%) ( Table 5) .
Techniques used for radiological guidance were similar for native kidney and graft biopsies (Figure 2A ). Real-time 
Monitoring after RB
The mean duration of in-hospital observation following RB was 24.8 ± 6.9 h for native kidney biopsies and 19.5 ± 8.5 h for graft biopsies (Table 5) . With regard to native kidney biopsies (84 answers), the observation time was >24 h for 8 (9.5%), 24 h for 71 (84.5%), 8-12 h for 2 (2.4%) and 4-8 h for 3 (3.6%) nephrologists. With regard to graft biopsies (45, 100%), the observation time was >24 h for 1 (2.2%), 24 h for 33 (73.3%) and 4-8 h for 11 (24.5%) nephrologists ( Figure 2B ). Early discharge (<12 h) was the rule in 3 (4.1%) units for native kidney biopsies and in 10 (28.6%) units for graft biopsies.
Ultrasound and haemoglobin measurement were systematically performed after RB procedures by 33 (37.5%) and 15 (17%) nephrologists, respectively (Table 5) .
Discussion
RB complications have been extensively studied in large prospective and retrospective studies [2, 4, 13, 16, 17] . Despite these extensive studies, several important issues remain unresolved for nephrologists performing renal biopsies. Technical advances, namely automated biopsy devices, US guidance [4, 18] and TJRB [7, 8] , have been shown to improve the safety and efficiency of RB procedures. However, the availability and spread of these techniques may be limited in 'real-world' clinical practice. We conducted a national survey regarding RB procedures in adults, particularly those concerning the screening and prevention of haemorrhagic complications. In all, 1013 nephrologists in activity were contacted for the study, although it was likely that RB were only performed by a small proportion. This study included answers from 74 distinct nephrology units-27 located in teaching hospitals, 35 located in public general hospitals and 12 located in private centres. The response rate was 71% for units in teaching hospitals (27 out of 38 units). Unfortunately, we were unable to provide response rates for nephrology units in general hospitals and private centres, as the total number of those types of units performing RB procedures in France is unknown. Native kidney and graft biopsies were performed in 73 and 35 units, respectively. RB activity was highly variable among units, ranging from several hundred to <10 per year. Overall, our results should be considered as representative of RB procedures in France.
From our data, it appeared that the modalities of patient information prior to RB should be improved. Indeed, both oral and written detailed information were only provided by 49 (55.7%) nephrologists, and written consent was only obtained by 39 (44.3%) nephrologists. Screening for haemorrhagic risk factors prior to RB procedures relies on patient questioning, haemostatic tests and consideration of specific risk factors. Our results indicate that patient questioning about personal and familial bleeding history is likely underperformed. Moreover, it is likely that many nephrologists are not familiar with this practice; thus, the use of questionnaires prepared by haemostasis experts should be encouraged.
Bleeding time was measured before RB by 50 (56.8%) nephrologists. However, bleeding time is not a good predictor of the risk of haemorrhage associated with surgical procedures and cannot reliably identify patients who have recently ingested antiplatelet agents; therefore, bleeding time (BT) is not recommended as a routine pre-operative test [19, 20] . Moreover, several studies failed to demonstrate a predictive value of BT for complications secondary to RB [2, 4, 13] . It is clear that BT without a careful assessment of personal and familial history of bleeding is inadequate to predict bleeding. Further studies would be necessary to determine the true value of BT in this setting and whether the empirical use of desmopressin has a favourable benefit/risk in patients with an isolated prolongation of BT.
Several reports identified risk factors of post-biopsy bleeding, such as high blood pressure, renal failure, obesity and age [4] [5] [6] 21] . In our study, the majority of nephrologists reported limit values for blood pressure and haemoglobin levels that, in their opinions, contraindicated percutaneous RB. The mean limit of reported blood pressure was ∼160/90 mmHg. However, previous reports [4, 6] have suggested that an upper limit value of 140/90 mmHg prior to an RB procedure would be more appropriate.
In general, there is no definitive way to predict which patients will develop complications, although several important factors that predispose to bleeding have been identified. Further studies will be required to determine how to integrate the results of haemostatic tests, and other risk factors, and to stratify the risk of bleeding.
RB performed on patients taking antiplatelets agents represents another important issue in clinical practice. Percutaneous RB after cessation of antiplatelet agents for several days was by far the most common attitude and was reported by >90% of nephrologists in our study. Surprisingly, this practice did not appear to be influenced by TJRB availability; nephrologists with adequate access to TJRB reported this practice even more frequently than those with inadequate access. This phenomenon could be related to the fact that TJRB is more frequently accessible in the largest centres, which perform the highest number of RB procedures and, therefore, are more experienced. TJRB has been reported to be a relatively safe and reliable technique for patients at high risk for bleeding [7] [8] [9] and should be considered in this setting. An effort should be made in France to improve TJRB availability, which was considered adequate in <40% of centres analysed. When TJRB is not available, the risk of antiplatelet agent cessation should be balanced with the risk of bleeding. A recent study showed relatively low complication rates in patients continuing antiplatelet agent and undergoing percutaneous RB [22] . However, in our opinion, this practice should be avoided whenever possible. Laparoscopic renal biopsy has also been reported as an alternative for patients for whom percutaneous RB is contraindicated [23, 24] . Nevertheless, general anaesthesia is necessary, and peri-operative risk is not null even in patients with mild co-morbidity. Surgical RB was never or only rarely performed in units participating in our study. To our knowledge, no study has compared the safety of percutaneous, transjugular and laparoscopic RB in patients at risk for bleeding, including those taking antiplatelet or anticoagulant drugs.
Correction of anaemia, DDAVP, oestrogens and cryoprecipitate (a blood product rich in factor VIII, von Willebrand factor and fibrinogen) have been shown to improve 'uraemic bleeding' [21] , which is the result of multifactorial alterations of haemostasis in a setting of chronic or acute renal failure. Cryoprecipitate is not available in France, and oestrogen use was not reported by nephrologists, in contrast to DDAVP, which was commonly administrated to high-risk patients.
Further studies will be necessary to establish the best way to manage high-risk patients and limit the risk of post-RB complications.
Procedures for percutaneous RB were relatively homogenous among the nephrologists queried in our study. Automated biopsy guns, which were used by the vast majority of nephrologists, should be used instead of the Tru-Cut needle. Several studies have suggested that 14-18G needles are the most appropriate sizes for this procedure [2, 25, 26] .
An automated biopsy gun combined with real-time US guidance was reported to provide adequate samples in ∼99% of cases, with severe haemorrhagic complications in <0.1%, thus representing a gold standard method [1, 4] . The use of US by nephrologists to assess the location and depth of the kidney at the patient's bedside without guidance was also reported to provide excellent results [27] . A minority of nephrologists performed RB without radiological control, which should not be recommended.
Controversies persist regarding the optimal duration of observation before discharge after RB [14] . In our study, almost all nephrologists reported observation times of at least 24 h after native kidney biopsies. Approximately 25% of nephrologists performed graft biopsies with observation times limited to 4-8 h. Several studies advocated the safety of early (6-8 h) discharge after biopsy [11, 12] . However, these studies included small numbers of patients (relative to expected complication rates) who were selected as low-risk patients, and the biopsies were generally performed by experienced nephrologists. Whittier et al. published a study regarding complications after 750 native kidney biopsies in adults. In this study, 67% and 89% of complications occurred within 8 and 24 h following RB, respectively, suggesting that early discharge may be dangerous after a native kidney biopsy [13] . In a multicentric study by Furness et al. that included 2127 protocol graft biopsies, only 9 (0.42%) severe complications occurred, all presenting within 4 h after biopsy [28] . In another study by our group, no severe complications were observed after 251 protocol graft biopsies [29] . Therefore, protocol graft biopsy, which was performed in nearly half of the units in our study, appears to be a relatively safe practice. In view of these data, we believe that early discharge after graft biopsy, but not after native kidney biopsy, may be considered in patients with no haemorrhagic risk factors.
US and haemoglobin were systematically performed after RB by some nephrologists. Systematic US after RB revealed perirenal haematoma in 40-90% of procedures [30, 31] . However, the haematomas were almost always asymptomatic, and such a finding usually occurs without therapeutic consequence. Systematic haemoglobin monitoring was also shown to be of little value in detecting complications after RB [13] . Therefore, systematic exams after RB procedures are not indicated.
We investigated whether the duration of observation after RB, use of bleeding time and limit of haemoglobin value allowing RB were linked to the centre's size and experience. No association was found between these factors and the number of RB performed (data not shown).
The most important limitation of our study was the lack of data available regarding the frequency of post-RB complications among the centres involved. A prospective study would be required to determine whether discrepancy in RB procedures translates into variations in complication rates or not.
In summary, our study provides a representative picture of 'everyday' RB practices in France. Our results may be of interest for nephrologists worldwide to compare their practices to those reported here. Analysis of RB procedures allowed us to emphasize several important issues in clinical practice that remain unaddressed. We hope that our results and discussion represent a preliminary step for the elaboration of guidelines for all aspects of RB practices.
